COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Multi-center Study on Therapy-oriented Molecular Subtyping of Hepatocellular Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03668158
Recruitment Status : Unknown
Verified October 2018 by Xiao Xu, Zhejiang University.
Recruitment status was:  Not yet recruiting
First Posted : September 12, 2018
Last Update Posted : October 24, 2018
Information provided by (Responsible Party):
Xiao Xu, Zhejiang University

Brief Summary:
The purpose of this study is to establish molecular subtyping of HCC.

Condition or disease
Hepatocellular Carcinoma

Detailed Description:
Hepatocellular carcinoma is one of the most common malignant tumors in the world with high incidence and mortality. Liver transplantation is the most effective treatment for HCC and is in high demand in China. However, recurrence of HCC among liver transplantation recipients is still a great challenge and threat to the survival of recipients. So it is of great significance to establish molecular subtyping of HCC and achieve precise selection of recipients. Based on large scales of samples, the investigator's study aims to establish multi-omics characteristic profiles of liver transplantation for HCC in integration of apparent biological characteristics, clinical management and prognostic information by utilizing genomics, transcriptomics and proteomics, etc. This study will contribute to the therapy-oriented molecular subtyping of HCC.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 500 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Multi-center Study on Therapy-oriented Molecular Subtyping of Hepatocellular Carcinoma
Estimated Study Start Date : November 20, 2018
Estimated Primary Completion Date : May 1, 2020
Estimated Study Completion Date : July 1, 2020

recurrent HCC
recurrent HCC after LT
non-recurrent HCC
non- recurrent HCC after LT

Primary Outcome Measures :
  1. recurrence rate [ Time Frame: 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Hospitalization patient

Inclusion Criteria:

Liver transplantation due to HCC within Hangzhou criteria

Exclusion Criteria:

Liver transplantation due to HCC beyond Hangzhou criteria Liver transplantation due to other disease except HCC Multiple organ transplantation

Layout table for additonal information
Responsible Party: Xiao Xu, Clinical Professor, Zhejiang University Identifier: NCT03668158    
Other Study ID Numbers: ZJHZXU2017
First Posted: September 12, 2018    Key Record Dates
Last Update Posted: October 24, 2018
Last Verified: October 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases